The Mucopolysaccharidosis Type I Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Mucopolysaccharidosis Type I Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mucopolysaccharidosis Type I Market.

Some of the key takeaways from the Mucopolysaccharidosis Type I Pipeline Report:

• Companies across the globe are diligently working toward developing novel Mucopolysaccharidosis Type I treatment therapies with a considerable amount of success over the years. 
• Mucopolysaccharidosis Type I companies working in the treatment market are Genevector Biotechnology, EdiGene Inc., therapeutics EdiGene Inc., Sigilon Therapeutics, REGENXBIO Inc., JCR Pharmaceuticals, Paradigm Biopharma, Jupiter Neurosciences, and others, are developing therapies for the Mucopolysaccharidosis Type I treatment 

• Emerging Mucopolysaccharidosis Type I therapies in the different phases of clinical trials are JWK-008 Chengdu, Research programme: oligonucleotide based RNA base editing therapeutics, SIG 005, RGX-111, JR-171, Pentosan Polysulphate, JNS102, and others are expected to have a significant impact on the Mucopolysaccharidosis Type I market in the coming years.   
• In Jan 2023, The FDA has approved the investigational new drug (IND) application for OTL-203, a hematopoietic stem cell (HSC) gene therapy being developed for the treatment of the Hurler subtype of mucopolysaccharidosis type I (MPS-IH), according to Orchard Therapeutics (Nasdaq: ORTX), a global leader in gene therapy. In the second half of 2023, the business anticipates starting a global registrational study to evaluate OTL-203’s effectiveness and safety to current standard of care
• In 2023, In order to cure severe Mucopolysaccharidosis Type I (MPS I), EGENXBIO has released encouraging interim results from the Phase I/II study of its investigational one-time gene therapy, RGX-111
• In February 2022, REGENXBIO Inc. announced positive interim data are being presented at the 18th Annual WORLDSymposium™ from five patients in the ongoing Phase I/II trial and one patient from a single-patient InvestigationalNew Drug (IND) application of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (MPS I)

Mucopolysaccharidosis Type I Overview

Known as a multisystem disorder, mucopolysaccharidosis type I (MPS I) is a rare hereditary condition that affects numerous body systems. MPS I is a member of the mucopolysaccharidoses, a wider group of diseases known as lysosomal storage disorders (LSDs), which are hereditary metabolic diseases.

Get a Free Sample PDF Report to know more about Mucopolysaccharidosis Type I Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/mucopolysaccharidosis-type-i-pipeline-insight

Emerging Mucopolysaccharidosis Type I Drugs Under Different Phases of Clinical Development Include:

• JWK-008 Chengdu: Genevector Biotechnology
• Research programme: oligonucleotide based RNA base editing therapeutics: EdiGene Inc.
• JR 171: JCR Pharmaceuticals
• RGX 111: REGENXBIO
• SIG 005: Sigilon Therapeutics
• RGX-111: REGENXBIO Inc.
• JR-171: JCR Pharmaceuticals
• Pentosan Polysulphate: Paradigm Biopharma
• JNS102: Jupiter Neurosciences

Route of Administration

Mucopolysaccharidosis Type I pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Mucopolysaccharidosis Type I Pipeline Therapeutics Assessment

• Mucopolysaccharidosis Type I Assessment by Product Type
• Mucopolysaccharidosis Type I By Stage and Product Type
• Mucopolysaccharidosis Type I Assessment by Route of Administration
• Mucopolysaccharidosis Type I By Stage and Route of Administration
• Mucopolysaccharidosis Type I Assessment by Molecule Type
• Mucopolysaccharidosis Type I by Stage and Molecule Type

DelveInsight’s Mucopolysaccharidosis Type I Report covers around 12+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Mucopolysaccharidosis Type I product details are provided in the report. Download the Mucopolysaccharidosis Type I pipeline report to learn more about the emerging Mucopolysaccharidosis Type I therapies

Some of the key companies in the Mucopolysaccharidosis Type I Therapeutics Market include:

Key companies developing therapies for Mucopolysaccharidosis Type I are – Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., Paradigm Biopharmaceuticals Ltd., and others.

Mucopolysaccharidosis Type I Pipeline Analysis:

The Mucopolysaccharidosis Type I pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Mucopolysaccharidosis Type I with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mucopolysaccharidosis Type I Treatment.
• Mucopolysaccharidosis Type I key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Mucopolysaccharidosis Type I Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mucopolysaccharidosis Type I market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Mucopolysaccharidosis Type I drugs and therapies

Mucopolysaccharidosis Type I Pipeline Market Drivers

• Increase in prevalence of Mucopolysaccharidosis type I, further understanding in pathogenesis are some of the important factors that are fueling the Mucopolysaccharidosis Type I Market.

Mucopolysaccharidosis Type I Pipeline Market Barriers

• However, lack of awareness of signs and symptoms of the disorder, challenges in predicting disease severity in newborn screening and other factors are creating obstacles in the Mucopolysaccharidosis Type I Market growth.

Scope of Mucopolysaccharidosis Type I Pipeline Drug Insight    

• Coverage: Global
• Key Mucopolysaccharidosis Type I Companies: Genevector Biotechnology, EdiGene Inc., therapeutics EdiGene Inc., Sigilon Therapeutics, REGENXBIO Inc., JCR Pharmaceuticals, Paradigm Biopharma, Jupiter Neurosciences, and others
• Key Mucopolysaccharidosis Type I Therapies: JWK-008 Chengdu, Research programme: oligonucleotide based RNA base editing therapeutics, SIG 005, RGX-111, JR-171, Pentosan Polysulphate, JNS102, and others
• Mucopolysaccharidosis Type I Therapeutic Assessment: Mucopolysaccharidosis Type I current marketed and Mucopolysaccharidosis Type I emerging therapies
• Mucopolysaccharidosis Type I Market Dynamics: Mucopolysaccharidosis Type I market drivers and Mucopolysaccharidosis Type I market barriers 

Request for Sample PDF Report for Mucopolysaccharidosis Type I Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services